Last edition
News about "Dr. Chris Yang"
AusperBio Doses First Patient in HBV Candidate AHB-171 Study
AusperBio has dosed the first patient in the AHB-171 clinical study, advancing its HBV pipeline and proprietary Au-HALO liver-targeting delivery technology siRNA platform.
Dr. Chris Yang | 03/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members